A lack of quality evidence comparing management strategies confounds complex treatment decisions for patients with high-risk prostate cancers. No randomized trial comparing surgery to radiation has been successfully completed.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Despite inherent selection biases, however, observational and registry data suggest improved outcomes for patients initially managed with prostatectomy. As consensus shifts away from aggressive treatment for low-risk disease and toward multimodal treatment of locally advanced and metastatic disease, there is renewed interest in surgery for local control in patients presenting with high-risk localized, node-positive and minimally metastatic disease. The objective of this review is to examine the evidence evaluating clinical outcomes of patients with high-risk clinically localized, node-positive and metastatic prostate cancer treated with radical prostatectomy.
Future oncology (London, England). 2016 Feb 03 [Epub ahead of print]
Benjamin T Ristau, David Cahn, Robert G Uzzo, Brian F Chapin, Marc C Smaldone
Division of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. , Division of Urology, Einstein Healthcare Network, Philadelphia, PA, USA. , Division of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. , Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. , Division of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.